The field of gene therapy is witnessing unprecedented advancements, marked by innovative treatments and expanding possibilities. As we navigate this dynamic landscape, it is crucial to centre our efforts around the very individuals these therapies aim to benefit—the patients. We recently attended the Royal Society of Medicine’s (RSM) “Unveiling Gene Therapy: Transforming medical practice through ATMPs” event. In this blog, Dan Gibson, Head of Collaborations at the Cell and Gene Therapy Catapult, reflects on his thoughts following the meeting, exploring how patient-centric approaches are not just a moral imperative but a scientific necessity for the future of gene therapy.